Close

Regeneron (REGN): Reluctance To Discuss Pricing Causes a PT Revision - Chardan

November 7, 2016 7:37 AM EST Send to a Friend
Chardan Capital Markets analyst, Gbola Amusa, reiterated his Sell rating on shares of Regeneron Pharma (NASDAQ: REGN) and cut the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login